TGTX · TG Therapeutics Inc
Price
Snapshot
50 fields · last close| Market Cap | $8.32B |
| P/E | 18.84 |
| Float | 141.6M |
| Beta | 1.82 |
| Volatility | 45.4% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Very High |
| Clavix score | 70.7 |
| Price | 56.58 |
| Change | +4.06% |
| Prev Close | 54.37 |
| Open | 54.08 |
| Day Low | 53.36 |
| Day High | 55.37 |
| Avg Vol | 2 |
| Avg $ Vol | $88.42M |
| 52W High | 59.30 |
| 52W Low | 26.76 |
| 52W Pos | 91.6% |
| From High | −4.59% |
| From Low | +111.43% |
| Max DD 1Y | −23.51% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +2.19% |
| SMA 50 | +4.91% |
| SMA 200 | +33.94% |
| RSI (14) | 48.6 |
| Vol 30D | 33.0% |
| Vol 90D | 44.9% |
| 1Y Range | 27–59 |
| Daily bars | 534 |
| Perf Week | +2.68% |
| Perf Month | +2.51% |
| Perf Quarter | −1.02% |
| Perf Half Y | +57.14% |
| Perf Year | +58.88% |
| Perf YTD | +93.24% |
| Prev Day | +4.06% |
| Clavix | B- |
| Debt / Eq | 0.15 |
| Curr Ratio | 4.10 |
| Int Cover | 3.7× |
| FCF Margin | −4.0% |
| Rev Growth | +87.3% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 20 / 35 |
Clavix risk grade
regraded every trading dayTGTX grades B-, 70.7 of 100. Steadiest on Sector Resilience (65), most exposed on Price Stability (55, mixed). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 20 of 35 in Biotechnology by Clavix score.
How rough the ride is
| TGTX | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.82 | 0.50 |
| Volatilityannualized | 45.4% | 14.3% |
| Max drawdown, past yearworst peak-to-trough fall | −23.5% | — |
| Typical daily movemedian absolute daily change | 1.50% | — |
| Days beyond ±3%of the last 252 sessions | 60 (24%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| TGTX | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.82 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| TGTX | |
|---|---|
| 1 week | +2.7% |
| 1 month | +2.5% |
| Year to date | +93.2% |
| 1 year | +58.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| TGTX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 16 since 4 Aug |
| Average score0 most bearish, 100 most bullish | 62 |
| Bullish · bearisharticles above 60 · below 40 | 11 · 3 |
| Directionarticles whose tone is improving vs worsening | 11 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| TGTX | |
|---|---|
| Revenue growthyear over year | +87.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openTG Therapeutics announced the publication of a five-year matching-adjusted indirect comparison of its MS drug BRIUMVI against ocrelizumab and ofatumumab in relapsing multiple sclerosis patients, using data from its Phase 3 ULTIMATE I/II trials to compare long-term relapse activity and disability outcomes.
Zacks Research raised its rating on TG Therapeutics from 'strong sell' to 'hold' in a research note on Tuesday.
TG Therapeutics said its multiple sclerosis drug BRIUMVI has captured more than one-third of the intravenous anti-CD20 market and is gaining share as it nears its fourth full year on sale, with the company targeting a $1 billion annual revenue run rate.
TG Therapeutics CEO Mike Weiss said the company's multiple sclerosis drug BRIUMVI has captured more than one-third of the intravenous anti-CD20 market and is gaining share as it nears its fourth year on the market. The headline suggests the company is targeting a $1 billion sales run rate for the product.
TG Therapeutics CEO Mike Weiss said the company's multiple sclerosis drug BRIUMVI now holds more than one-third of the IV anti-CD20 market (drugs that target B-cells, a type of immune cell) as it nears its fourth year on the market, and the company is targeting a $1 billion annual revenue run rate. The article body was truncated, so additional details were not available.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $8.25B | — | 1.33 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.55B | 79.37 | 0.40 | Compare |
| CYTK | Cytokinetics Inc | B+ | $8.82B | — | 0.41 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $8.82B | 106.80 | 1.19 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| TWST | Twist Bioscience Corp | D+ | $9.75B | — | 2.15 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $7.10B | — | 0.38 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.79B | 40.23 | 0.64 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.